This study is testing whether adding a new immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with advanced prostate cancer live longer without their cancer getting worse. About 150 men whose cancer has spread and stopped responding to hormon…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC